Imbalanced dopaminergic transmission mediated by serotonergic neurons in L-DOPA-induced dyskinesia

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Navailles, Sylvia ^a   De Deurwaerdre, Philippe ^a  

^a INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; DOPAMINE; FLUOXETINE; LEVODOPA; SEROTONIN; SEROTONIN 1A RECEPTOR;

ARTICLE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG MEGADOSE; DYSKINESIA; FOREBRAIN; HIPPOCAMPUS; HUMAN; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL; SUBSTANTIA NIGRA PARS RETICULATA;

EID: 84855262928     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/323686     Document Type: Article

References (153)

1. Dorsey E. R., Constantinescu R., Thompson J. P., Biglan K. M., Holloway R. G., Kieburtz K., Marshall F. J., Ravina B. M., Schifitto G., Siderowf A., Tanner C. M., Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 2007 68 5 384 386 (Pubitemid 46184217)
2. Hornykiewicz O., Dopamine (3-hydroxytyramine) and brain function Pharmacological Reviews 1966 18 2 925 964
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F., Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations Journal of the Neurological Sciences 1973 20 4 415 455
4. Cotzias G. C., L-Dopa for Parkinsonism New England Journal of Medicine 1968 278 11 630
5. Hornykiewicz O., Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA) British Medical Bulletin 1973 29 2 172 178
6. Ahlskog J. E., Muenter M. D., Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Movement Disorders 2001 16 3 448 458 (Pubitemid 36041148)
7. Jankovic J., Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations Movement Disorders 2005 20 11 S11 S16 (Pubitemid 40846906)
8. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci Nilsson M. A., Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease European Journal of Neuroscience 2002 15 1 120 132 (Pubitemid 35478015)
9. Cenci M. A., Ohlin K. E., Rodent models of treatment-induced motor complications in Parkinson's disease Parkinsonism and Related Disorders 2009 15 supplement 4 S13 S17
10. Ungerstedt U., 6-hydroxy-dopamine induced degeneration of central monoamine neurons European Journal of Pharmacology 1968 5 1 107 110
11. Olsson M., Nikkhah G., Bentlage C., Bjorklund A., Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test Journal of Neuroscience 1995 15 5 3863 3875
12. Cenci M. A., L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment Parkinsonism and Related Disorders 2007 13 3 S263 S267 (Pubitemid 351215253)
13. Ungerstedt U., Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system Acta Physiologica Scandinavica 1971 367, supplement 69 93
14. Ungerstedt U., Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour Acta Physiologica Scandinavica 1971 367, supplement 49 68
15. Zetterstrom T., Herrera-Marschitz M., Ungerstedt U., Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis Brain Research 1986 376 1 1 7 (Pubitemid 16046010)
16. Bunney B. S., Aghajanian G. K., Roth R. H., Comparison of effects of L dopa amphetamine and apomorphine on firing rate of rat dopaminergic neurones Nature New Biology 1973 245 143 123 125
17. Mercuri N. B., Calabresi P., Bernardi G., Responses of rat substantia nigra compacta neurones to L-DOPA British Journal of Pharmacology 1990 100 2 257 260 (Pubitemid 20170639)
18. Harden D. G., Grace A. A., Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment Journal of Neuroscience 1995 15 9 6157 6166
19. Maeda T., Kannari K., Suda T., Matsunaga M., Loss of regulation by presynaptic dopamine D2 receptors of exogenous L- DOPA-derived dopamine release in the dopaminergic denervated striatum Brain Research 1999 817 1-2 185 191 (Pubitemid 29225359)
20. Miller D. W., Abercrombie E. D., Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats Journal of Neurochemistry 1999 72 4 1516 1522 (Pubitemid 29140823)
21. Sarre S., De Klippel N., Herregodts P., Ebinger G., Michotte Y., Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-Parkinsonian rat studied with microdialysis Naunyn-Schmiedeberg's Archives of Pharmacology 1994 350 1 15 21 (Pubitemid 24214243)
22. Kannari K., Tanaka H., Maeda T., Tomiyama M., Suda T., Matsunaga M., Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation Journal of Neurochemistry 2000 74 1 263 269 (Pubitemid 30012777)
23. Lee W. Y., Chang J. W., Nemeth N. L., Kang U. J., Vesicular monoamine transporter-2 and aromatic l-amino acid decarboxylase enhance dopamine delivery after L-3,4-dihydroxyphenylalanine administration in parkinsonian rats Journal of Neuroscience 1999 19 8 3266 3274 (Pubitemid 29174018)
24. Navailles S., Carta M., Guthrie M., De Deurwaerdere P., L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinsons disease. Central Nervous System Agents in Medicinal Chemistry. In press
25. Ng L. K., Chase T. N., Colburn R. W., Kopin I. J., l-dopa-induced release of cerebral monoamines Science 1970 170 953 76 77
26. Tison F., Mons N., Geffard M., Henry P., The metabolism of exogenous L-Dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain Journal of Neural Transmission 1991 3 1 27 39
27. Arai R., Karasawa N., Geffard M., Nagatsu I., L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study Neuroscience Letters 1995 195 3 195 198
28. Yamada H., Aimi Y., Nagatsu I., Taki K., Kudo M., Arai R., Immunohistochemical detection of l-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats Neuroscience Research 2007 59 1 1 7 (Pubitemid 47285387)
29. Ng L. K., Colburn R. W., Kopin I. J., Effects of L-dopa on accumulation and efflux of monoamines in particles of rat brain homogenates Journal of Pharmacology and Experimental Therapeutics 1972 183 2 316 325
30. Ng L. K., Chase T. N., Colburn R. W., Kopin I. J., L-dopa in Parkinsonism. A possible mechanism of action Neurology 1972 22 7 688 696
31. Navailles S., Bioulac B., Gross C., De Deurwaerdre P., Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease Neurobiology of Disease 2010 38 1 136 143
32. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M., Role of serotonergic neuron in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats NeuroReport 1999 10 3 631 634 (Pubitemid 29333295)
33. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., Matsunaga M., Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation Journal of Neurochemistry 2001 76 5 1346 1353 (Pubitemid 32198239)
34. Yamato H., Kannari K., Shen H., Suda T., Matsunaga M., Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum NeuroReport 2001 12 6 1123 1126 (Pubitemid 32374729)
35. Sprouse J. S., Aghajanian G. K., Electrophysiological responses of serotonergic dorsal raphe enurons to 5-HT1A and 5-HT1B agonists Synapse 1987 1 1 3 9 (Pubitemid 17114243)
36. Bosker F. J., De Winter T. Y. C. E., Klompmakers A. A., Westenberg H. G. M., Flesinoxan dose-dependently reduces extracellular 5-hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT1A receptors Journal of Neurochemistry 1996 66 6 2546 2555
37. Knobelman D. A., Kung H. F., Lucki I., Regulation of extracellular concentrations of 5-hydroxytryptamine (5- HT)in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors Journal of Pharmacology and Experimental Therapeutics 2000 292 3 1111 1117 (Pubitemid 30136608)
38. Riad M., Garcia S., Watkins K. C., Jodoin N., Doucet., Langlois X., El Mestikawy S., Hamon M., Descarries L., Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain Journal of Comparative Neurology 2000 417 2 181 194 (Pubitemid 30038263)
39. Sharp T., Bramwell S. R., Hjorth S., Grahame-Smith D. G., Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis British Journal of Pharmacology 1989 98 3 989 997 (Pubitemid 19269825)
40. Adell A., Carceller A., Artigas F., In vivo brain dialysis study of the somatodendritic release of serotonin in the raphe nuclei of the rat: effects of 8-hydroxy-2-(di- n-propylamino)tetralin Journal of Neurochemistry 1993 60 5 1673 1681 (Pubitemid 23127570)
41. Casanovas J. M., Artigas F., Differential effects of ipsapirone on 5-hydroxytryptamine release in the dorsal and median raphe neuronal pathways Journal of Neurochemistry 1996 67 5 1945 1952 (Pubitemid 26349667)
42. Arborelius L., Nomikos G. G., Grillner P., Hertel P., Backlund Hook B., Hacksell U., Svensson T. H., 5-HT(1A) receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram Naunyn-Schmiedeberg's Archives of Pharmacology 1995 352 2 157 165
43. Temel Y., Boothman L. J., Blokland A., Magill P. J., Steinbusch H. W. M., Visser-Vandewalle V., Sharp T., Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus Proceedings of the National Academy of Sciences of the United States of America 2007 104 43 17087 17092 (Pubitemid 350210996)
44. Navailles S., Benazzouz A., Bioulac B., Gross C., De Deurwaerdre P., High-frequency stimulation of the subthalamic nucleus and L-3,4- dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease Journal of Neuroscience 2010 30 6 2356 2364
45. Navailles S., Bioulac B., Gross C., De Deurwaerdre P., Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease Neurobiology of Disease 2011 41 2 585 590
46. Azmitia E. C., Segal M., An autoradiographic analysis of the different ascending projections of the dorsal and median raphe nuclei in the rat Journal of Comparative Neurology 1978 179 3 641 667 (Pubitemid 8372646)
47. Steinbusch H. W., Bjrklund A., Hkfelt T., Kuhar M. J., Serotonin-immunoreactive neurons and their projections in the CNS Handbook of Chemical NeuroanatomyClassical Transmitters and Transmitters Receptors in the CNS Part II 1984 Amsterdam,The Netherlands 68 125
48. Lindgren H. S., Andersson D. R., Lagerkvist S., Nissbrandt H., Cenci M. A., L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia Journal of Neurochemistry 2010 112 6 1465 1476
49. Obeso J. A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temio B., Mena-Segovia J., Rodrguez M., Olanow C. W., The basal ganglia in Parkinson's disease: current concepts and unexplained observations Annals of Neurology 2008 64 2 S30 S46
50. Seeman P., Brain dopamine receptors Pharmacological Reviews 1980 32 3 229 313
51. Brown W. D., Taylor M. D., Roberts A. D., Oakes T. R., Schueller M. J., Holden J. E., Malischke L. M., DeJesus O. T., Nickles R. J., FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa Neurology 1999 53 6 1212 1218 (Pubitemid 29480078)
52. Kostrzewa R. M., Dopamine receptor supersensitivity Neuroscience and Biobehavioral Reviews 1995 19 1 1 17
53. Tong J., Fitzmaurice P. S., Ang L. C., Furukawa Y., Guttman M., Kish S. J., Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy Annals of Neurology 2004 55 1 125 129 (Pubitemid 38067371)
54. Ahmed M. R., Berthet A., Bychkov E., Porras G., Li Q., Bioulac B. H., Carl Y. T., Bloch B., Kook S., Aubert I., Dovero S., Doudnikoff E., Gurevich V. V., Gurevich E. V., Bezard E., Lentiviral overexpression of GRK6 alleviates L-Dopa-induced dyskinesia in experimental parkinson's disease Science Translational Medicine 2010 2 28 28 ra28
55. Rylander D., Parent M., O-Sullivan S. S., Dovero S., Lees A. J., Bezard E., Descarries L., Cenci M. A., Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Annals of Neurology 2010 68 5 619 628
56. Zeng B. Y., Iravani M. M., Jackson M. J., Rose S., Parent A., Jenner P., Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiology of Disease 2010 40 3 599 607
57. Chase T. N., Levodopa therapy: consequences of the nonphysiologic replacement of dopamine Neurology 1998 50 supplement 5 S17 S25 (Pubitemid 28223748)
58. Olanow C. W., Obeso J. A., Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors Neurology 2000 55 11 supplement 4 S72 SS77
59. De La Fuente-Fernndez R., Sossi V., Huang Z., Furtado S., Lu J. Q., Calne D. B., Ruth T. J., Stoessl A. J., Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain 2004 127 12 2747 2754 (Pubitemid 39627382)
60. Cenci M. A., Lundblad M., Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia Journal of Neurochemistry 2006 99 2 381 392 (Pubitemid 44477196)
61. Carta M., Carlsson T., Kirik D., Bjrklund A., Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats Brain 2007 130 7 1819 1833 (Pubitemid 47343795)
62. Carta M., Carlsson T., Muoz A., Kirik D., Bjrklund A., Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias Progress in Brain Research 2008 172 465 478
63. Ulusoy A., Sahin G., Kirik D., Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats Proceedings of the National Academy of Sciences of the United States of America 2010 107 29 13159 13164
64. Muoz A., Carlsson T., Tronci E., Kirik D., Bjrklund A., Carta M., Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model Experimental Neurology 2009 219 1 298 307
65. Marin C., Aguilar E., Rodrguez-Oroz M. C., Bartoszyk G. D., Obeso J. A., Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats Psychopharmacology 2009 204 2 241 250
66. Sarre S., Herregodts P., Deleu D., Devrieze A., De Klippel N., Ebinger G., Michotte Y., Biotransformation of L-DOPA in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study Naunyn-Schmiedeberg's Archives of Pharmacology 1992 346 3 277 285
67. Sarre S., Smolders I., Thorré K., Ebinger G., Michotte Y., Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study Journal of Neural Transmission 1997 104 11-12 1215 1228 (Pubitemid 28031815)
68. Orosz D., Bennett J. P., Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the hemiparkinsonian rat Experimental Neurology 1992 115 3 388 393
69. Di Matteo V., Pierucci M., Esposito E., Crescimanno G., Benigno A., Di Giovanni G., Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders Progress in Brain Research 2008 172 423 463
70. Putterman D. B., Munhall A. C., Kozell L. B., Belknap J. K., Johnson S. W., Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease Journal of Pharmacology and Experimental Therapeutics 2007 323 1 277 284 (Pubitemid 47443278)
71. Thorré K., Sarre S., Smolders I., Ebinger G., Michotte Y., Dopaminergic regulation of serotonin release in the substantia nigra of the freely moving rat using microdialysis Brain Research 1998 796 1-2 107 116 (Pubitemid 28343239)
72. Gil S. J., Park C. H., Lee J. E., Minn Y. K., Koh H. C., Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats Brain Research Bulletin 2011 96 6 1718 1727
73. Lundblad M., Af Bjerkén S., Cenci M. A., Pomerleau F., Gerhardt G. A., Strmberg I., Chronic intermittent L-DOPA treatment induces changes in dopamine release Journal of Neurochemistry 2009 108 4 998 1008
74. Gil S., Park C., Lee J., Koh H., The roles of striatal serotonin and l-amino-acid decarboxylase on l-DOPA-induced dyskinesia in a hemiparkinsonian rat model Cellular and Molecular Neurobiology 2010 30 6 817 825
75. Zhang X., Andren P. E., Greengard P., Svenningsson P., Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism Proceedings of the National Academy of Sciences of the United States of America 2008 105 6 2163 2168 (Pubitemid 351439482)
76. Zhang X., Andren P. E., Svenningsson P., Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model Physiology and Behavior 2007 92 1-2 29 33 (Pubitemid 47374252)
77. Huot P., Johnston T. H., Koprich J. B., Winkelmolen L., Fox S. H., Brotchie J. M., Regulation of cortical and striatal 5-HT(1A) receptors in the MPTP-lesioned macaque. Neurobiology of Aging. In press
78. Riahi G., Morissette M., Parent M., Di Paolo T., Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias European Journal of Neuroscience 2011 33 10 1823 1831
79. Nicholson S. L., Brotchie J. M., 5-Hydroxytryptamine (5-HT, serotonin) and Parkinson's diseaseopportunities for novel therapeutics to reduce the problems of levodopa therapy European Journal of Neurology 2002 9 supplement 3 1 6 (Pubitemid 35471977)
80. Fox S. H., Brotchie J. M., 5-HT(2C) receptor binding is increased in the substantia Nigra pars reticulata in Parkinson's disease Movement Disorders 2000 15 6 1064 1069
81. Meissner W., Ravenscroft P., Reese R., Harnack D., Morgenstern R., Kupsch A., Klitgaard H., Bioulac B., Gross C. E., Bezard E., Boraud T., Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine Neurobiology of Disease 2006 22 3 586 598 (Pubitemid 43832130)
82. Fox S. H., Chuang R., Brotchie J. M., Serotonin and Parkinson's disease: on movement, mood, and madness Movement Disorders 2009 24 9 1255 1266
83. Scholtissen B., Verhey F. R. J., Adam J. J., Weber W., Leentjens A. F. G., Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance Clinical Neuropharmacology 2006 29 5 276 285 (Pubitemid 44440001)
84. Carta M., Lindgren H. S., Lundblad M., Stancampiano R., Fadda F., Cenci M. A., Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats Journal of Neurochemistry 2006 96 6 1718 1727 (Pubitemid 43351629)
85. Eskow K. L., Dupre K. B., Barnum C. J., Dickinson S. O., Park J. Y., Bishop C., The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats Synapse 2009 63 7 610 620
86. Bartholini G., Da Prada M., Pletscher A., Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase Journal of Pharmacy and Pharmacology 1968 20 3 228 229
87. Everett G. M., Borcherding J. W., L-dopa: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice Science 1970 168 3933 849 850
88. Tohgi H., Abe T., Takahashi S., Takahashi J., Hamato H., Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration Neuroscience Letters 1993 159 1-2 135 138 (Pubitemid 23283257)
89. Hery F., Simonnet G., Bourgoin S., Effect of nerve activity on the in vivo release of [3H]serotonin continuously formed from L-[3H]tryptophan in the caudate nucleus of the cat Brain Research 1979 169 2 317 334 (Pubitemid 9211560)
90. Blier P., Serrano A., Scatton B., Differential responsiveness of the rat dorsal and median raphe 5-HT systems to 5-HT1 receptor agonists and p-chloroamphetamine Synapse 1990 5 2 120 133 (Pubitemid 20095103)
91. Kreiss D. S., Lucki I., Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT(1A) autoreceptors of the dorsal and median raphe nuclei Journal of Pharmacology and Experimental Therapeutics 1994 269 3 1268 1279 (Pubitemid 24204214)
92. Hervs I., Bel N., Fernndez A. G., Palacios J. M., Artigas F., In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei Naunyn-Schmiedeberg's Archives of Pharmacology 1998 358 3 315 322 (Pubitemid 28425487)
93. Invernizzi R., Carli M., Di Clemente A., Samanin R., Administration of 8-hydroxy-2-(di-n-propylamino)tetralin in raphe nuclei dorsalis and medianus reduces serotonin synthesis in the rat brain: differences in potency and regional sensitivity Journal of Neurochemistry 1991 56 1 243 247 (Pubitemid 21901955)
94. Invernizzi R., Velasco C., Bramante M., Longo A., Samanin R., Effect of 5-HT(1A) receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus Neuropharmacology 1997 36 4-5 467 473 (Pubitemid 27272092)
95. Casanovas J. M., Lésourd M., Artigas F., The effect of the selective 5-HT(1A) agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain British Journal of Pharmacology 1997 122 4 733 741 (Pubitemid 27453100)
96. Romero L., Artigas F., Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT(1A) receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors Journal of Neurochemistry 1997 68 6 2593 2603 (Pubitemid 27218184)
97. Amilhon B., Lepicard E., Renoir T., Mongeau R., Popa D., Poirel O., Miot S., Gras C., Gardier A. M., Gallego J., Hamon M., Lanfumey L., Gasnier B., Giros B., El Mestikawy S., VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety Journal of Neuroscience 2010 30 6 2198 2210
98. McQuade R., Sharp T., Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis Journal of Neurochemistry 1997 69 2 791 796 (Pubitemid 27327983)
99. Gaspar P., Cases O., Maroteaux L., The developmental role of serotonin: news from mouse molecular genetics Nature Reviews Neuroscience 2003 4 12 1002 1012 (Pubitemid 37486676)
100. Kiyasova V., Fernandez S. P., Laine J., Stankovski L., Muzerelle A., Doly S., Gaspar P., A genetically defined morphologically and functionally unique subset of 5-HT neurons in the mouse raphe nuclei Journal of Neuroscience 2011 31 8 2756 2768
101. Picconi B., Pisani A., Barone I., Bonsi P., Centonze D., Bernardi G., Calabresi P., Pathological synaptic plasticity in the striatum: implications for parkinson's disease NeuroToxicology 2005 26 5 779 783 (Pubitemid 41427517)
102. Picconi B., Ghiglieri V., Calabresi P., L-3,4-dihydroxyphenylalanine- induced sprouting of serotonin axon terminals: a useful biomarker for dyskinesias? Annals of Neurology 2010 68 5 578 580
103. Prescott I. A., Dostrovsky J. O., Moro E., Hodaie M., Lozano A. M., Hutchison W. D., Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients Brain 2009 132 2 309 318
104. Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E., Bloch B., Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia Journal of Neuroscience 2009 29 15 4829 4835
105. Frechilla D., Cobreros A., Saldise L., Moratalla R., Insausti R., Luquin M. R., Del Ro J., Serotonin 5-HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic Parkinsonian monkeys Synapse 2001 39 4 288 296 (Pubitemid 32128650)
106. Doder M., Rabiner E. A., Turjanski N., Lees A. J., Brooks D. J., Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study Neurology 2003 60 4 601 605 (Pubitemid 36246076)
107. Kish S. J., Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Advances in Neurology 2003 91 39 49
108. Scholtissen B., Verhey F. R. J., Steinbusch H. W. M., Leentjens A. F. G., Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data Journal of Neural Transmission 2006 113 1 59 73 (Pubitemid 41828957)
109. Jellinger K. A., Pathology of Parkinson's disease: changes other than the nigrostriatal pathway Molecular and Chemical Neuropathology 1991 14 3 153 197
110. Halliday G. M., Blumbergs P. C., Cotton R. G. H., Blessing W. W., Geffen L. B., Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease Brain Research 1990 510 1 104 107 (Pubitemid 20060808)
111. Kovacs G. G., Klppel S., Fischer I., Dorner S., Lindeck-Pozza E., Birner P., Btefr I. C., Pilz P., Volk B., Budka H., Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders NeuroReport 2003 14 1 73 76 (Pubitemid 36160745)
112. Chen C. P. L. H., Alder J. T., Bray L., Kingsbury A. E., Francis P. T., Foster O. J. F., Post-synaptic 5-HT(1A) and 5-HT(2A) receptors are increased in Parkinson's disease neocortex Annals of the New York Academy of Sciences 1998 861 288 289 (Pubitemid 29047755)
113. Kish S. J., Tong J., Hornykiewicz O., Rajput A., Chang L. J., Guttman M., Furukawa Y., Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain 2008 131 1 120 131
114. Castro M. E., Pascual J., Romn T., Berciano J., Figols J., Pazos A., 5-HT(1B) receptor binding in degenerative movement disorders Brain Research 1998 790 1-2 323 328 (Pubitemid 28234519)
115. Quirion R., Richard J., Differential effects of selective lesions of cholinergic and dopaminergic neurons on serotonin-type 1 receptors in rat brain Synapse 1987 1 1 124 130 (Pubitemid 17114255)
116. Ikeguchi K., Kuroda A., Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs European Archives of Psychiatry and Clinical Neuroscience 1995 244 6 320 324
117. Durif F., Vidailhet M., Assal F., Roche C., Bonnet A. M., Agid Y., Low-dose clozapine improves dyskinesias in Parkinson's disease Neurology 1997 48 3 658 662 (Pubitemid 27120102)
118. Di Giovanni G., Di Matteo V., Pierucci M., Benigno A., Esposito E., Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2c receptor be a new target for therapeutic strategies? Current Medicinal Chemistry 2006 13 25 3069 3081 (Pubitemid 44509709)
119. De Deurwaerdre P., Mignon L., Chesselet M. F., Di Giovanni G., Neve K., Physiological and pathophysiological aspects of 5-HT 2C receptors in basal ganglia The Pathophysiology of Central 5-HT 2C Receptors 2010 New York, NY, USA Humana Press, Springer The receptors series
120. Fox S. H., Moser B., Brotchie J. M., Behavioral effects of 5-HT(2C) receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease Experimental Neurology 1998 151 1 35 49 (Pubitemid 28223854)
121. Fox S. H., Brotchie J. M., 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D1 receptor agonists in the 6-hydroxydopamine-lesioned rat European Journal of Pharmacology 2000 398 1 59 64 (Pubitemid 30336677)
122. De Deurwaerdre P., Chesselet M. F., Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats Journal of Neuroscience 2000 20 13 5170 5178
123. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D. J., Piccini P., Staging of serotonergic dysfunction in Parkinson's Disease: an in vivo 11C-DASB PET study Neurobiology of Disease 2010 40 1 216 221
124. Muoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Bjrklund A., Bezard E., Carta M., Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain 2008 131 12 3380 3394
125. Goodwin G. M., De Souza R. J., Wood A. J., Green A. R., The enhancement by lithium of the 5-HT(1A) mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism Psychopharmacology 1986 90 4 488 493 (Pubitemid 17096777)
126. Yamada J., Sugimoto Y., Horisaka K., The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice European Journal of Pharmacology 1988 154 3 299 304
127. Kuan W. L., Zhao J. W., Barker R. A., The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram Psychopharmacology 2008 197 2 279 293
128. Schettino L. F., Adamovich S. V., Hening W., Tunik E., Sage J., Poizner H., Hand preshaping in Parkinson's disease: effects of visual feedback and medication state Experimental Brain Research 2006 168 1-2 186 202 (Pubitemid 41752824)
129. Dagher A., Nagano-Saito A., Functional and anatomical magnetic resonance imaging in Parkinson's disease Molecular Imaging and Biology 2007 9 4 234 242 (Pubitemid 47028739)
130. Robertson G. S., Robertson H. A., Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms Journal of Neuroscience 1989 9 9 3326 3331 (Pubitemid 19260845)
131. Antonini A., Schwarz J., Oertel W. H., Pogarell O., Leenders K. L., Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride Movement Disorders 1997 12 1 33 38 (Pubitemid 27032877)
132. Kuriakose R., Stoessl A. J., Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications Progress in Brain Research 2010 184 177 192
133. Encarnacion E. V., Hauser R. A., Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments European Neurology 2008 60 2 57 66
134. Soghomonian J. J., L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus European Journal of Neuroscience 2006 23 9 2395 2403
135. Svenningsson P., Arts J., Gunne L., Andren P. E., Acute and repeated treatment with L-DOPA increase c-jun expression in the 6-hydroxydopamine- lesioned forebrain of rats and common marmosets Brain Research 2002 955 1-2 8 15 (Pubitemid 35284830)
136. Xu Y., Sun S., Cao X., Effect of levodopa chronic administration on behavioral changes and fos expression in basal ganglia in rat model of PD Journal of Huazhong University of Science and Technology. Medical sciences 2003 23 3 258 262
137. Berthet A., Bezard E., Dopamine receptors and L-dopa-induced dyskinesia Parkinsonism and Related Disorders 2009 15 supplement 4 S8 S12
138. Calabresi P., Giacomini P., Centonze D., Bernardi G., Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Annals of Neurology 2000 47 4, supplement 1 S60 S69 (Pubitemid 30192011)
139. Guigoni C., Li Q., Aubert I., Dovero S., Bioulac B. H., Bloch B., Crossman A. R., Gross C. E., Bezard E., Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia Journal of Neuroscience 2005 25 8 2102 2107 (Pubitemid 40289415)
140. Gong L., Kostrzewa R. M., Fuller R. W., Perry K. W., Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA- lesioned rats is mediated through a serotonin system Journal of Pharmacology and Experimental Therapeutics 1992 261 3 1000 1007
141. Beyeler A., Kadiri N., Navailles S., Boujema M. B., Gonon F., Moine C. L., Gross C., De Deurwaerdre P., Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia Neuroscience 2010 169 1 158 170
142. Kapur S., Remington G., Serotonin-dopamine interaction and its relevance to schizophrenia American Journal of Psychiatry 1996 153 4 466 476 (Pubitemid 26113309)
143. Liégeois J. F., Ichikawa J., Meltzer H. Y., 5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner Brain Research 2002 947 2 157 165
144. Meco G., Stirpe P., Edito F., Purcaro C., Valente M., Bernardi S., Vanacore N., Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study Journal of Neural Transmission 2009 116 7 881 884
145. Carlsson M., Carlsson A., Interactions between glutamatergic and monoaminergic systems within the basal gangliaimplications for schizophrenia and Parkinson's disease Trends in Neurosciences 1990 13 7 272 276 (Pubitemid 20193457)
146. Wolf E., Seppi K., Katzenschlager R., Hochschorner G., Ransmayr G., Schwingenschuh P., Ott E., Kloiber I., Haubenberger D., Auff E., Poewe W., Long-term antidyskinetic efficacy of amantadine in Parkinson's disease Movement Disorders 2010 25 10 1357 1363
147. Navailles S., De Deurwaerdre P., Presynaptic control of serotonin on striatal dopamine function Psychopharmacology 2010 213 2-3 213 242
148. Gomez-Mancilla B., Bedard P. J., Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP- treated monkeys Clinical Neuropharmacology 1993 16 5 418 427 (Pubitemid 23292096)
149. Goetz C. G., Damier P., Hicking C., Laska E., Mller T., Olanow C. W., Rascol O., Russ H., Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Movement Disorders 2007 22 2 179 186 (Pubitemid 46374758)
150. Eskow K. L., Gupta V., Alam S., Park J. Y., Bishop C., The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy Pharmacology Biochemistry and Behavior 2007 87 3 306 314 (Pubitemid 47101876)
151. Kannari K., Kurahashi K., Tomiyama M., Maeda T., Arai A., Baba M., Suda T., Matsunaga M., Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease Brain and Nerve 2002 54 2 133 137 (Pubitemid 34742080)
152. Iravani M. M., Tayarani-Binazir K., Chu W. B., Jackson M. J., Jenner P., In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability Journal of Pharmacology and Experimental Therapeutics 2006 319 3 1225 1234
153. Tomiyama M., Kimura T., Maeda T., Kannari K., Matsunaga M., Baba M., A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease Neuroscience Research 2005 52 2 185 194 (Pubitemid 40704601)